Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDER Deputy Galson Brings Risk Management Experience To FDA Surveillance

Executive Summary

FDA Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, has experience in public health risk assessment that will contribute to the center's revamping of its postmarketing surveillance program.
Advertisement

Related Content

Former CDER Chief Galson Moving To Amgen
PDUFA’s Fairy Godmother: Woodcock Steps Into Breach As Acting CDER Chief
FDA Drug Safety Upgrades Coming; Medicare Bill Could Help Win Funding
CDER Deputy Galson Will Run Drug Center For At Least Six Months
CDER Organizational Development Team To Be Headed By EPA’s Wright
CDER Deputy Director Galson To Head Drug Center For Several Months
Postmarketing Surveillance Will Report To Deputy Galson Under CDER Reorg.
FDA Drug Name Guidance Will Address Labeling and Packaging-Related Errors
FDA Drug Name Guidance Will Address Labeling and Packaging-Related Errors
FDA-Australia cGMP agreement
Advertisement
UsernamePublicRestriction

Register

PS037578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel